ConductScience.org, home

Library / Trials

Longitudinal Assessment of Biomarkers Among Patients With MDD

NCT07931001, Recruiting, Massachusetts General Hospital

Trial 9

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

FieldValueSource
TitleLongitudinal Assessment of Biomarkers Among Patients With MDDClinicalTrials.gov
NCT numberNCT07931001ClinicalTrials.gov
StatusRecruitingClinicalTrials.gov
Enrollment100 participants, estimatedClinicalTrials.gov
Lead sponsorMassachusetts General HospitalClinicalTrials.gov
ConditionsMajor Depressive Disorder (MDD)ClinicalTrials.gov
InterventionsNo Intervention: Observational CohortClinicalTrials.gov
First posted2026-11-12ClinicalTrials.gov
Last updated2026-11-12ClinicalTrials.gov

Registered outcomes 4

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescriptionSource
PrimaryMontgomery Åsberg Depression Rating Scale (MADRS)From baseline to Week 4The MADRS is a clinician-based assessment of depressive symptoms. Higher scores indicate worse symptoms. Total score can range from 0 to 60.ClinicalTrials.gov
SecondaryGeneralized Anxiety Disorder-7 (GAD-7)At baseline, Week 2, and Week 4The GAD-7 is a self-report questionnaire that assesses anxiety symptoms. Total scores range from 0 to 21, with higher scores indicating more severe anxiety symptoms.ClinicalTrials.gov
SecondaryQuick Inventory of Depressive Symptomatology (QIDS-SR16)At baseline, Week 2, and Week 4The QIDS-SR16 is a self-report questionnaire that assesses depressive symptom severity. Total scores range from 0 to 27, with higher scores indicating more severe depressive symptoms.ClinicalTrials.gov
SecondaryInsomnia Severity Index (ISI)At baseline, Week 2, and Week 4The ISI is a self-report questionnaire that assesses the severity of insomnia symptoms. Total scores range from 0 to 28, with higher scores indicating more severe insomnia symptoms.ClinicalTrials.gov

Outcomes 0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

TypeOutcomeTime framePopulationUnitsMeasured asSource

Results by group 0

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnitsSource

Participant flow 0

How many started, completed or left each group, period by period.

PeriodMilestoneGroupParticipantsUnits countedSource

Adverse events 0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

TypeEventOrgan systemGroupAffectedAt riskEventsSource

Adverse event totals 0

The totals the trial posted for each group.

TotalGroupAffectedAt riskSource

Papers 0

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource

Trial comparisons 0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

ComparisonSource

Tests 0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

TestNamed asSource

Source 4

FieldValueSource
Releasetrials-2026-11-12-0.3.0ClinicalTrials.gov
Release manifest SHA-2564a570df2e7274cee2d4fa2959402fab41880e2cd412e4b590390035fbea69391ClinicalTrials.gov
Registry capture2026-11-12ClinicalTrials.gov
Results copy, AACT2026-03-23ClinicalTrials.gov

The same record as JSON

Release trials-2026-11-12-0.3.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.